{"id":"NCT01017952","sponsor":"GlaxoSmithKline","briefTitle":"A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-25","primaryCompletion":"2011-10-01","completion":"2011-10-17","firstPosted":"2009-11-23","resultsPosted":"2013-08-19","lastUpdate":"2018-08-31"},"enrollment":1635,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"FF/GW642444 Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"GW642444 Inhalation Powder","otherNames":[]}],"arms":[{"label":"FF/GW642444 Inhalation Powder 100/25 mcg QD","type":"EXPERIMENTAL"},{"label":"FF/GW642444 Inhalation Powder 50mcg/25mcg QD","type":"EXPERIMENTAL"},{"label":"FF/GW642444 Inhalation Powder 200/25 mcg QD","type":"EXPERIMENTAL"},{"label":"GW642444 25mcg QD","type":"EXPERIMENTAL"}],"summary":"The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)","primaryOutcome":{"measure":"Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean","timeFrame":"From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal","effectByArm":[{"arm":"VI 25 µg QD","deltaMin":1.14,"sd":null},{"arm":"FF/VI 50/25 µg QD","deltaMin":0.92,"sd":null},{"arm":"FF/VI 100/25 µg QD","deltaMin":0.9,"sd":null},{"arm":"FF/VI 200/25 µg QD","deltaMin":0.79,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.040"},{"comp":"OG000 vs OG002","p":"0.024"},{"comp":"OG000 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":24},"locations":{"siteCount":183,"countries":["United States","Argentina","Australia","Canada","Chile","Denmark","Germany","Italy","Mexico","Netherlands","Peru","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["24429127","31197640","27251682","25490706","24314123"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":66,"n":409},"commonTop":["Nasopharyngitis","Oral candidiasis","Upper respiratory tract infection","Headache","Sinusitis"]}}